Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.

Published

Journal Article

Medarex and Bristol-Myers Squibb are developing ipilimumab, an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4, for the potential combination or monotherapy treatment of melanoma, prostate, breast, renal and other cancers, as well as HIV infection.

Full Text

Duke Authors

Cited Authors

  • Morse, MA

Published Date

  • December 2005

Published In

Volume / Issue

  • 7 / 6

Start / End Page

  • 588 - 597

PubMed ID

  • 16370382

Pubmed Central ID

  • 16370382

Electronic International Standard Serial Number (EISSN)

  • 2040-3445

International Standard Serial Number (ISSN)

  • 1464-8431

Language

  • eng